Bayer Schering Pharma, Prometheus Reach Agreement on Oncology Mutational Analyses | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories and Bayer Schering Pharma today said they have executed an oncology-focused mutational analyses services agreement, building on a deal reached between the two parties earlier this year.

Information gleaned from the new agreement may lead to better patient stratification in clinical studies and hasten the development of new cancer diagnostics and treatments, Prometheus said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.